Transfusion safety: Where are we today?

Annals of the New York Academy of Sciences

Volumn 1054, Issue , 2005, Pages 325-341

  Luban, Naomi L C ^a,b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Post transfusion infections; Red blood cell transfusions; TRALI; Transfusion related lung injury

Indexed keywords

ALLOIMMUNIZATION; AUTOIMMUNITY; BACTERIUM CONTAMINATION; BLOOD DONOR; BLOOD TRANSFUSION; CANADA; CONFERENCE PAPER; CYTOMEGALOVIRUS; DEVELOPING COUNTRY; ERYTHROCYTE TRANSFUSION; EUROPEAN UNION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS; INFECTION RISK; JAPAN; SAFETY; TRANSFUSION RELATED ACUTE LUNG INJURY; TREATMENT INDICATION; UNITED STATES; VIREMIA; WEST NILE FLAVIVIRUS;

BACTERIA (MICROORGANISMS); CYTOMEGALOVIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; WEST NILE VIRUS;

EID: 29744451951     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1345.040     Document Type: Conference Paper

References (39)

1. BLAJCHMAN, M.A. 2004. Bacterial contamination of cellular blood components: risks, sources and control. Vox Sang. 87: 98-103.
2. KUEHNERT, M.J., V.R. ROTH, R. HALEY, et al. 2001. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 41: 1493-1499.
3. WAGNER, S.J. 2004. Transfusion-transmitted bacterial infection: risks, sources and interventions. Vox Sang. 86: 157-163.
4. CORASH, L. 2003. Pathogen reduction technology: methods, status of clinical trials and future prospects. Curr. Hematol. Rep. 2: 495-502.
5. LING, A.E., K.E. ROBBINS, T.M. BROWN, et al. 2000. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA 284: 210-214.
6. DELWART, E.L., N.D. KALMIN, T.S. JONES, et al. 2004. First report of human immunodeficiency virus transmission via an RNA-screened blood donation. Vox Sang. 86: 171-177.
7. STRAMER, S.L., L. CHAMBERS, P.L. PAGE, et al. 2003. Third reported US case of breakthrough HIV transmission from NAT screened blood. Transfusion 43: 40A-S134-040K.
8. BUSCH, M.P., S.A. GLYNN, S.L. STRAMER, et al. 2005. A new strategy for estimating risks of transfusion-transmitted viral infection based on rates of detection of recently infected donors. Transfusion 45: 254-264.
9. DODD, R.Y., E.P. NOTARI IV & S.L. STRAMER. 2002. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 42: 975-979.
10. KLEINMAN, S., P. CHAN & P. ROBILLARD. 2003. Risk associated with transfusion of cellular blood components in Canada. Transfus. Med. Rev. 17: 120-162.
11. TONG, M.J., N.S. EL-FARRA, A.R. REIKES, et al. 1995. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 332: 1463-1466.
12. CASIRAGHI, M.A., M. DE PASCHALE, L. ROMANO, et al. 2004. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 39: 90-96.
13. STRICKLAND, D.K., C.A. RIELY, C.C. PATRICK, et al. 2000. Hepatitis C infection among survivors of childhood cancer. Blood 95: 3065-3070.
14. BADIZADEGAN, K., M.M. JONAS, M.J. OTT, et al. 1998. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 28: 1416-1423.
15. NI, Y., M. CHANG, K. LIN, et al. 1996. Hepatitis C viral infection in thalassemic children: clinical and molecular studies. Pediatr. Res. 39: 323-328.
16. VOGT, M., T. LANG, G. FROSNER, et al. 1999. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N. Engl. J. Med. 341: 866-870.
17. PRATI, D., M. MAGGIONI, S. MILANI, et al. 2004. Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica 89: 1179-1186.
18. ALTER, H.J., Y. NAKATSUJI, J. MELPOLDER, et al. 1997. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N. Engl. J. Med. 336: 747-754.
19. ALTER, H.J. 1997. G-pers creepers, where'd you get those papers? A reassessment of the literature on the hepatitis G virus. Transfusion 37: 569-572.
20. ALTER, M., M. GALLAGHER, T. MORRIS, et al. 1997. Acute non A-E hepatitis in the United States and the role of hepatitis G infection. N. Engl. J. Med. 336: 741-746.
21. TILLMANN, H.L., H. HEIKEN, A. KNAPIK-BOTOR, et al. 2001. Infection with GB virus C and reduced mortality among HIV-infected patients. N. Engl. J. Med. 345: 715-724.
22. KIEM, H.P., D. MYERSON, R. STORB, et al. 1997. Prevalence of hepatitis G virus in patients with aplastic anemia. Blood 90: 1335-1336.
23. KLEINMAN, S.H., J.C. NILAND, S.P. AZEN, et al. 1989. Prevalence of antibodies to human immunodeficiency virus type 1 among blood donors prior to screening. The Transfusion Safety Study/NHLBI Donor Repository. Transfusion 29: 572-580.
24. JONES, D.S., R.H. BYERS, T.J. BUSH, et al. 1993. Epidemiology of transfusion-associated acquired immunodeficiency syndrome in children in the United States, 1981 through 1989. Pediatrics 89: 123-127.
25. LIEB, L.E., T.M. MUNDY, D. GOLDFINGER, et al. 1995. Unrecognized human immunodeficiency virus type 1 infection in a cohort of transfused neonates: a retrospective investigation. Pediatrics 95: 717-721.
26. WAYNE, C., M. CORNELL, R. O'DONNELL, et al. 1993. Seroprevalence of HIV in a transfused pediatric cardiac cohort in a high prevalence area. Transfusion 33: 544.
27. BOWDEN, R.A., S.J. SLIGHTER, M. SAYERS, et al. 1995. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86: 3598-3603.
28. BROWN, K.E., N.S. YOUNG, B.M. ALVING, et al. 2001. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion 41: 130-135.
29. ZANELLA, A., F. ROSSI, C. CESANA, et al. 1995. Transfusion-transmitted human parvovirus B19 infection in a thalassemic patient. Transfusion 35: 769-772.
30. UK reports potential case of transfusion-transmitted vCJD. 2003. AABB Weekly Report 9: 1.
31. MCCULLOUGH, J., D. ANDERSON & D. BROOKIE. 2004. Consensus conference on vCJD screening of blood donors: report of the panel. Transfusion 44: 675-683.
32. Update: Investigations of West Nile Virus Infections in Recipients of Organ Transplantation and Blood Transfusion. 2002. CDC MMWR 51: 879.
33. MATSUBAYASHI, K., Y. NAGAOKA, H. SAKATA, et al. 2004. Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. Transfusion 44: 934-940.
34. PRATI, D., C. CAPELLI, P. REBULLA, et al. 1998. The current risk of retroviral infections transmitted by transfusion in patients who have undergone multiple transfusions. Cooleycare Cooperative Group. Arch. Intern. Med. 158: 1566-1569.
35. PRATI, D., A. ZANELLA, P. BOSONI, et al. 1998. The incidence and natural course of transfusion-associated GB virus C/hepatitis G virus infection in a cohort of thalassemic patients. The Cooleycare Cooperative Group. Blood 91: 774-777.
36. CHAN, P.K., K. CHIK, C. LI, et al. 2001. Prevalence and genotype distribution of TT virus in various specimen types from thalassaemic patients. J. Viral Hepat. 8: 304-309.
37. VAMVAKAS, E.C. 2004. White blood cell containing allogeneic blood transfusion, post-operative infection and mortality: a meta-analysis of observational "before-and-after" studies. Vox Sang. 86: 111-119.
38. KLEINMAN, S., T. CAULFIELD, P. CHAN, et al. 2004. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 44: 1774-1789.
39. HASHIMOTO, M.N., E.Y. KIMURA, M. YAMAMOTO, et al. 2004. Expression of Fas and Fas ligand on spleen T cells of experimental animals after unmodified or leukoreduced allogeneic blood transfusions. Transfusion 44: 158-163.